Search for a trial

A phase I study on Dendritic cells loaded with allogeneous cell lysate (Alloys) in patients with mesothelioma as maintenance treatment (AlloDen)

The objective of the present trial is to investigate the safety of an allogenic tumor cell lysate loaded onto autologuous dendritic cells (AlloDen) in patients with malignant mesothelioma (MM). Heretoo we will perform a phase I study with a…

A phase II trial of TTFields in addition to pemetrexed and cisplatin or carboplatin as first-line
treatment in malignant pleural mesothelioma

Primary Objective:* To determine if TTFields in combination with pemetrexed/platinum improves overall survival (OS) compared to historical control in patients with unresectable mesothelioma.Secondary Objectives:* To evaluate the overall response…

LUME-Meso: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma

To evaluate the safety and efficacy in terms of progression-free survival (PFS) and overall survival (OS) of nintedanib + pemetrexed / cisplatin followed by nintedanib versus placebo + pemetrexed / cisplatin followed by placebo as first line…

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS 6063 in Subjects with Malignant Pleural Mesothelioma

Primary Efficacy Objectives• To compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving VS-6063 or placebo.• To compare the progression free survival (PFS) in subjects with malignant pleural mesothelioma receiving…

NGR015: Randomised double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)

Primary:• To compare overall survival (OS) in patientsrandomized to NGR-hTNF plus BIC versuspatients randomized to placebo plus BICSecondary:• To compare progression-free survival (PFS)• To compare disease control rate (DCR, defined asthe percentage…

An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma

The primary objective is to determine the effect on progression-free survival (PFS) of adding MORAb-009 to the combination of pemetrexed and cisplatin in the treatment of subjects with unresectable malignant pleural mesothelioma (MPM). (Protocol ch…

Phase II study of Cetuximab combined with Cisplatin or Carboplatin/Pemetrexed as first line treatment in patients with malignant pleural mesothelioma

By adding Cetuximab to standard treatment, we hope to prolonge progression free survival

An Open Label Phase II Multicentre Clinical Trial of Single Agent VELCADETM (Bortezomib) in Patients with Malignant Pleural Mesothelioma

To find activity in this new class of drugs

A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study

Primary Objective* To determine the DCR (disease control rate) at 12 weeks of nivolumab monotherapy in patients with progressive MPM.Secondary Objectives* To determine the safety of nivolumab monotherapy in patients with progressive MPM* To…

PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients.

Primary: 1. To determine the objective response rate (ORR), defined by Modified (i)RECIST criteria for pleural mesothelioma, of the combination of pembrolizumab - lenvatinib in pre-treated patients with MPM. Secondary:1. To describe the safety of…

Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma - a Phase I/II Dose Escalation and Safety Study

This study has been transitioned to CTIS with ID 2024-516738-36-00 check the CTIS register for the current data. The primary purpose of this study is to determine the maximum tolerable dose (MTD) of IP monotherapy with paclitaxel for patients with…

Phase I, Open-Label Study With Dendritic Cell therapy (MesoPher) In Combination With Ex-tended-Pleurectomy/Decortication After Chemotherapy in Subjects With Resectable Mesothelioma.

This study has been transitioned to CTIS with ID 2024-514054-70-00 check the CTIS register for the current data. To assess whether (neo)-adjuvant DCT in combination with eP/D is feasible in early stage epithelioid MPM patients after first-line…

An open-label, multi-center, Phase I study of oral IAG933 in adult patients with advanced Mesothelioma and other solid tumors

This study has been transitioned to CTIS with ID 2023-508369-34-00 check the CTIS register for the current data. The purpose of this first-in-human (FIH) study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD…

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma

To assess the feasibility of administering DCBI after CRS-HIPEC in patients with malignant peritoneal mesothelioma.

Ipilimumab and Nivolumab in the Treatment of malignant Pleural Mesothelioma: a Phase II study

The primary objective of the study is the disease control rate (DCR) at 12 weeks of the combination treatment of Nivolumab and Ipilimumab in patients with progressive MPM.The secondary objectives are:- to determine the safety profile of the…

CLE in diagnosing pleural malignancies, a comparison with pathology

To describe criteria on CLE-imaging of different entities (thoracic wall/ pleura/ fibrosis/ mediastinum) compared to histology.